Royal Bank Of Canada Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $202.00

Becton, Dickinson and Company (NYSE:BDX) had its price target decreased by equities researchers at Royal Bank Of Canada from $211.00 to $202.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “sector perform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 14.90% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Piper Sandler reduced their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $203.50.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $1.58 during trading on Friday, reaching $175.81. The company had a trading volume of 1,397,150 shares, compared to its average volume of 2,446,241. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $50.39 billion, a P/E ratio of 31.58, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a fifty day moving average of $187.07 and a two-hundred day moving average of $182.55.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 1,032 shares of company stock valued at $193,040. 0.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its stake in Becton, Dickinson and Company by 42.6% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 1,745 shares of the medical instruments supplier’s stock valued at $400,000 after buying an additional 521 shares during the last quarter. Cornerstone Planning Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares during the period. Leavell Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 6.7% in the 1st quarter. Leavell Investment Management Inc. now owns 9,986 shares of the medical instruments supplier’s stock worth $2,287,000 after buying an additional 630 shares during the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of Becton, Dickinson and Company by 174.6% in the first quarter. Cerity Partners LLC now owns 195,850 shares of the medical instruments supplier’s stock worth $44,862,000 after acquiring an additional 124,522 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.